StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) SEC filings

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.98−0.06 (-0.99%)

Close on Nov 13, 2026Market cap $323.91MP/E –Yield –

SEC filings

15 of Eikon Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Quarterly report10-QSep 30, 2026Nov 12, 2026SEC EDGAR
Current report8-KNov 12, 2026Nov 12, 2026SEC EDGAR
Current report8-KOct 26, 2026Oct 26, 2026SEC EDGAR
Current report8-KOct 23, 2026Oct 23, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 14, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 13, 2026SEC EDGAR
Current report8-KJul 31, 2026Aug 3, 2026SEC EDGAR
Current report8-KJun 5, 2026Jun 10, 2026SEC EDGAR
Current report8-KMay 30, 2026Jun 1, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 11, 2026SEC EDGAR
Current report8-KMay 11, 2026May 11, 2026SEC EDGAR
Current report8-KMar 30, 2026Mar 30, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 30, 2026SEC EDGAR
Current report8-KFeb 6, 2026Feb 6, 2026SEC EDGAR

See a number that looks wrong?